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comprehend the underlying factors relating QOL, utility,
and WTP.
QL2
CLINICAL IMPROVEMENT AND
RESPONSIVENESS OF PHYSICAL FUNCTION
MEASURES:TREATMENT WITH CTLA4IG 
(BMS-188667) IN PATIENTS WITH ACTIVE
RHEUMATOID ARTHRITIS
Li T,Williams GR, L’Italien G, Kawabata H, Nuamah I
Bristol-Myers Squibb, Princeton, NJ, USA
OBJECTIVES: To examine the treatment effect of
CTLA4Ig on physical function and to evaluate the
responsiveness of different domains of physical function
compared to tender joint count, a highly sensitive efﬁcacy
measure for rheumatoid arthritis (RA). METHODS: In a
randomized, double blind, placebo-controlled trial, 339
subjects with active RA receiving methotrexate (MTX)
were randomized to 3 treatment arms (CTLA4Ig 2 or 10
mg/kg and placebo) given intravenously once monthly.
The Modiﬁed Health Assessment Questionnaire (mHAQ)
was used to assess physical function and was adminis-
tered monthly. It consisted of questions assessing eight
domains of physical function: dressing, arising, eating,
walking, hygiene, reach, grip, and common activities.
Mean change from baseline in the mHAQ scores were
compared between the CTLA4Ig and the placebo groups.
Relative efﬁciency of mHAQ domains were calculated as
(SESmHAQ / SEStender joint count)2, with SES denotes standard-
ized effect size. A relative efﬁciency >1 suggested that the
domain was more efﬁcient than the tender joint count in
detecting the observed treatment effect. RESULTS: At 
6 months, the mHAQ summary score improved 42% 
for the CTLA4Ig 10mg/kg group compared to 14% for
the placebo group. This improvement was considered to
be clinically meaningful based on the commonly accepted
threshold. Patients in the 10mg/kg group also experi-
enced statistically signiﬁcant improvements compared to
the placebo group in the following domains: eating (32%
more improvement), hygiene (32% more), grip (24%
more), dressing (20% more), and walking (16% more).
Moreover, these physical domains were shown to be as
responsive as the tender joint count to detect a treatment
effect, with relative efﬁciencies close to one. CONCLU-
SIONS: treatment with CTLA4Ig signiﬁcantly improved
physical function in patients with active RA, especially in
areas related to eating, hygiene, grip, and walking ability.
Measures in physical function are efﬁcient in detecting
clinical improvements important to patients.
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DIABETIC PATIENTS’ WILLINGNESS TO PAY
FOR DIABETES EDUCATION BY PHARMACISTS:
VALIDITY OF CONTINGENT VALUATION
METHOD
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OBJECTIVES: This study was conducted to measure dia-
betic patients’ willingness-to-pay (WTP) for diabetes edu-
cation provided by pharmacists utilizing the contingent
valuation method, to determine factors which inﬂuence
patients’ WTP, and to test starting point bias and scope
effects. METHODS: Diabetic patients, randomly selected
at 2 hospital endocrinology clinics, were interviewed 
to measure their WTP for education resulting in 3 
hypothetical risk-reductions in diabetic complications
(reduction from 75% without education to 37.5% with
education, 50%®25%, and 25%®12.5%) using a
bidding game with randomly assigned starting amounts
($10/$40). Sample mean (SM) and mean based on log-
normal distribution (LNM) were calculated. Mean WTP
was calculated using 2-part model (PM) with a smear 
estimator, and Heckman 2-stage model (HM) for sample
selection correction, which were further used to 
determine signiﬁcant factors inﬂuencing WTP amount.
RESULTS: A total of 283 patients were interviewed.
Patients’ mean age and household income was 53.5 years
and $60,202 respectively. In total, 59% of patients were
willing-to-pay. SMs were $36 ± $49 for 75%Æ37.5%;
$35 ± $50 for 50%Æ25%; and $26 ± $42 for
25%Æ12.5%. SMs were similar to LNMs. Means based
on HM were $41 ± $23 for the 75%Æ37.5%, $38 ± $19
for 50%Æ25%; and $27 ± $16 for 25%Æ12.5%, which
were nearly the same as means calculated based on PM.
In HM model, patients were willing-to-pay signiﬁcantly
larger amounts as risk-reduction level increased (P <
0.001), as starting amount increased (P < 0.001), and if
neuropathy was present (P < 0.001). Patients’ age, race,
hemoglobin A1c, type of diabetes, and history of retinopa-
thy were not signiﬁcant factors in predicting WTP
amount. CONCLUSIONS: Patients, on average, were
willing-to-pay between $26 and $41 for pharmacist 
provided diabetes education, depending on risk reduction
level (scope effect) and starting amounts (starting point
bias). The contingent valuation method is useful for 
determining the economic value of pharmacists’ educa-
tion. Further investigations are recommended to elucidate
factors inﬂuencing patients’ WTP for a variety of other
services.
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SMOKING STATUS AND HEALTH-RELATED
QUALITY OF LIFE (HRQOL): FINDINGS FROM
THE BEHAVIORAL RISK FACTOR
SURVEILLANCE SYSTEM (BRFSS) DATA
Mody RR, Smith MJ
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Smoking is one of the leading causes of
preventable mortality in the United States. The beneﬁts
of smoking cessation have been well documented, and
understanding the relationship between smoking and
